Selvita and the University of Oxford join forces to tackle Parkinson’s disease

The Polish drug discovery and service provider Selvita has announced a new collaboration with the University of Oxford to advance …

ASCO 2023: Summit Therapeutics plans to rise with bispecific NSCLC data

Summit Therapeutics has announced data for its novel investigational bispecific antibody, ivonescimab, known as SMT112 or AK112 in a non-small …

ASCO 2023: Research backs chemo-only approach for some rectal cancer patients

Results unveiled at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting indicate that some patients with locally advanced …

ITM raises $273 million to fund radionuclide therapy pipeline

ITM (Isotope Technologies Munich) has announced a €255 million ($273.16 million) equity investment funding raise.  According to ITM’s CEO Steffen …

Simurosertib by Millennium Pharmaceuticals for Rectal Cancer: Likelihood of Approval

Simurosertib is under clinical development by Millennium Pharmaceuticals and currently in Phase I for Rectal Cancer. According to GlobalData, Phase …